PMID- 31230157
OWN - NLM
STAT- MEDLINE
DCOM- 20200511
LR  - 20221207
IS  - 1432-0843 (Electronic)
IS  - 0344-5704 (Linking)
VI  - 84
IP  - 3
DP  - 2019 Sep
TI  - The efficacy and safety of nab paclitaxel plus gemcitabine in elderly patients 
      over 75 years with unresectable pancreatic cancer compared with younger patients.
PG  - 647-654
LID - 10.1007/s00280-019-03895-2 [doi]
AB  - PURPOSE: To evaluate the efficacy and safety of nab paclitaxel (nab-P) plus 
      gemcitabine (GEM) in elderly patients >/= 75 years old with unresectable pancreatic 
      cancer (PC) compared with younger patients. METHODS: The data of 27 unresectable 
      PC patients treated with nab-P plus GEM as first-line chemotherapy were 
      retrospectively analyzed. The patients were divided into two groups according to 
      their age at inclusion: an elderly group (9 patients >/= 75 years old) and a 
      younger group (18 patients <75 years old). We compared the disease control rate, 
      median overall survival (OS), and adverse events (AEs) between the two groups. 
      Predictive factors for the OS were also evaluated. RESULTS: The clinical 
      characteristics of patients of the two groups were not significantly different 
      except for the age. The respective values for the disease control rate (66.7% vs. 
      77.8%, P = 0.542) and median OS (277 days vs. 312 days, P = 0.722) were also not 
      significantly different between the elderly and younger group, although the 
      relative dose intensity of GEM/nab-P in the elderly group (56.6%/53.1%) was 
      significantly lower than that in the younger group (67.3%/63.1%) 
      (P = 0.016/0.04). The absence of biliary drainage and CEA >/= 6.5 were found to be 
      poor prognostic factors in a multivariate analysis. The most common grade >/= 3 AE 
      was neutropenia (44% in both groups). No significant differences in the frequency 
      of all AEs were observed between the two groups. CONCLUSIONS: Nab-P plus GEM 
      appears effective and well-tolerated for elderly patients >/= 75 years old with 
      unresectable PC.
FAU - Ishimoto, Utako
AU  - Ishimoto U
AD  - Division of Gastroenterology and Hepatology, The Jikei University Daisan 
      Hospital, 4-11-1 Izumihon-cho, Komae-shi, Tokyo, 201-8601, Japan.
FAU - Kinoshita, Akiyoshi
AU  - Kinoshita A
AUID- ORCID: 0000-0002-6546-4485
AD  - Division of Gastroenterology and Hepatology, The Jikei University Daisan 
      Hospital, 4-11-1 Izumihon-cho, Komae-shi, Tokyo, 201-8601, Japan. 
      aki.kino@jikei.ac.jp.
FAU - Hirose, Yuki
AU  - Hirose Y
AD  - Division of Gastroenterology and Hepatology, The Jikei University Daisan 
      Hospital, 4-11-1 Izumihon-cho, Komae-shi, Tokyo, 201-8601, Japan.
FAU - Shibata, Keiko
AU  - Shibata K
AD  - Division of Gastroenterology and Hepatology, The Jikei University Daisan 
      Hospital, 4-11-1 Izumihon-cho, Komae-shi, Tokyo, 201-8601, Japan.
FAU - Ishii, Ayako
AU  - Ishii A
AD  - Division of Gastroenterology and Hepatology, The Jikei University Daisan 
      Hospital, 4-11-1 Izumihon-cho, Komae-shi, Tokyo, 201-8601, Japan.
FAU - Shoji, Ryo
AU  - Shoji R
AD  - Division of Gastroenterology and Hepatology, The Jikei University Daisan 
      Hospital, 4-11-1 Izumihon-cho, Komae-shi, Tokyo, 201-8601, Japan.
FAU - Yokota, Takeharu
AU  - Yokota T
AD  - Division of Gastroenterology and Hepatology, The Jikei University Daisan 
      Hospital, 4-11-1 Izumihon-cho, Komae-shi, Tokyo, 201-8601, Japan.
FAU - Iwaku, Akira
AU  - Iwaku A
AD  - Division of Gastroenterology and Hepatology, The Jikei University Daisan 
      Hospital, 4-11-1 Izumihon-cho, Komae-shi, Tokyo, 201-8601, Japan.
FAU - Mizuno, Yusuke
AU  - Mizuno Y
AD  - Division of Gastroenterology and Hepatology, The Jikei University Daisan 
      Hospital, 4-11-1 Izumihon-cho, Komae-shi, Tokyo, 201-8601, Japan.
FAU - Koike, Kazuhiko
AU  - Koike K
AD  - Division of Gastroenterology and Hepatology, The Jikei University Daisan 
      Hospital, 4-11-1 Izumihon-cho, Komae-shi, Tokyo, 201-8601, Japan.
FAU - Saruta, Masayuki
AU  - Saruta M
AD  - Division of Gastroenterology and Hepatology, Department of Internal Medicine, the 
      Jikei University School of Medicine, 3-25-8 Nishishinbashi, Minato-ku, Tokyo, 
      105-8461, Japan.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20190622
PL  - Germany
TA  - Cancer Chemother Pharmacol
JT  - Cancer chemotherapy and pharmacology
JID - 7806519
RN  - 0 (130-nm albumin-bound paclitaxel)
RN  - 0 (Albumins)
RN  - 0W860991D6 (Deoxycytidine)
RN  - P88XT4IS4D (Paclitaxel)
RN  - 0 (Gemcitabine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Albumins/administration & dosage
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Deoxycytidine/administration & dosage/analogs & derivatives
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Liver Neoplasms/*drug therapy/secondary
MH  - Lung Neoplasms/*drug therapy/secondary
MH  - Lymphatic Metastasis
MH  - Male
MH  - Middle Aged
MH  - Paclitaxel/administration & dosage
MH  - Pancreatic Neoplasms/*drug therapy/pathology
MH  - Patient Safety
MH  - Peritoneal Neoplasms/*drug therapy/secondary
MH  - Prognosis
MH  - Retrospective Studies
MH  - Survival Rate
MH  - Treatment Outcome
MH  - Gemcitabine
OTO - NOTNLM
OT  - Elderly
OT  - Gemcitabine
OT  - Nab paclitaxel
OT  - Pancreatic cancer
EDAT- 2019/06/24 06:00
MHDA- 2020/05/12 06:00
CRDT- 2019/06/24 06:00
PHST- 2019/05/06 00:00 [received]
PHST- 2019/06/14 00:00 [accepted]
PHST- 2019/06/24 06:00 [pubmed]
PHST- 2020/05/12 06:00 [medline]
PHST- 2019/06/24 06:00 [entrez]
AID - 10.1007/s00280-019-03895-2 [pii]
AID - 10.1007/s00280-019-03895-2 [doi]
PST - ppublish
SO  - Cancer Chemother Pharmacol. 2019 Sep;84(3):647-654. doi: 
      10.1007/s00280-019-03895-2. Epub 2019 Jun 22.